| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_00a421ab71bd49a451d0a49d23a082c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_170b45be8865dd99c0f64346244c8e76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d34cfa603c8c6685c5841c5b7e32f6e9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-241 |
| filingDate |
2009-03-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84699b0d7d3be599ab2cea7e5e6dcf81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81a7e7d8328dcdfb057fcb1db0054266 |
| publicationDate |
2009-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2009117791-A2 |
| titleOfInvention |
Mucosal gene signatures |
| abstract |
Infliximab (IFX) is effective treatment for Crohn's disease (CD) and ulcerative colitis (UC) not responding to standard therapy. 30-40% of patients do not improve and response is often incomplete. The aim of this study is to identify mucosal gene signatures predictive of response to EFX using high-density oligonucleotide arrays. Eight UC patients and 12 CD patients showed healing. In UC, only one probe set was differentially expressed in responders compared with non-responders, ie IL-13Ralpha2. At PAM analysis 2 probe sets, representing IL-13Ralpha2 and IL-I l, separated IBD responders from non-responders with an overall misclassification error rate of 0.046 (2/43), with 100% sensitivity and 91.3 % specificity. The IL-13Ralpha2 probe set was a top-ranked probe set in all our analyses using both LIMMA and PAM strategies. Our gene array studies of mucosal biopsies identified IL-13Ralpha2 in IBD as a predictor of (non-)response to IFX. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4015651-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011135024-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022128708-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102495215-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9651560-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019025624-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102884433-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3867399-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3655433-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9063151-B2 |
| priorityDate |
2008-03-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |